title: [Analysis of pulmonary function in leukemia patients after bone marrow transplantation: effects of prior chemotherapy].
abstract: To evaluate the effects of prior chemotherapy on pulmonary function after bone marrow transplantation(BMT), pulmonary function tests were performed prior to and after BMT on 7 acute leukemia (AL) and 13 chronic myelogenous leukemia (CML) patients given with CY (60 mg/kg x 2 days), total body irradiation (3 Gy x 4 days, 10 cGy/min), and CyA plus short-term MTX. No patient had graft-versus-host disease or lung complications. Pulmonary function after BMT did not deteriorate in the AL patients; however, both %Vital Capacity(%VC) and DL/VA decreased significantly in the CML patients (%VC before BMT: 112.1 +/- 11.5%, after BMT: 93.7 +/- 9.4%; DL/VA before BMT: 79.2 +/- 14.6%, after BMT: 54.1 +/- 10.6%). Although prior regimens of busulfan (BU) or interferon (IFN) were equal risk factors for decreased %VC after BMT, decreases in DV/VA were more significant in CML patients who received IFN. CML patients, especially those who have received BU or IFN, should be carefully monitored for pulmonary function to prevent respiratory failure after BMT.
authors.affiliation: First Department of Internal Medicine, Nihon University School of Medicine.
authors.forename: Y
authors.initials: Y
authors.lastname: Hatta
authors.forename: T
authors.initials: T
authors.lastname: Itoh
authors.forename: M
authors.initials: M
authors.lastname: Baba
authors.forename: H
authors.initials: H
authors.lastname: Shimojima
authors.forename: T
authors.initials: T
authors.lastname: Miyajima
authors.forename: T
authors.initials: T
authors.lastname: Izumi
authors.forename: A
authors.initials: A
authors.lastname: Horikoshi
authors.forename: J
authors.initials: J
authors.lastname: Takeuchi
authors.forename: U
authors.initials: U
authors.lastname: Sawada
authors.forename: T
authors.initials: T
authors.lastname: Horie
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000009:adverse effects; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007372:Interferons / Q000009:adverse effects; D007938:Leukemia / Q000503:physiopathology* / Q000628:therapy*; D008168:Lung / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D012129:Respiratory Function Tests; D012131:Respiratory Insufficiency / Q000209:etiology / Q000517:prevention & control; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014916:Whole-Body Irradiation / Q000009:adverse effects
chemical_list: D007166:Immunosuppressive Agents; D007372:Interferons; D002066:Busulfan